Asthma drug meets main goal of study to treat smokers’ lungs
UK drugmaker GSK said its asthma drug Nucala has achieved the primary endpoint of a late-stage study in patients with chronic obstructive pulmonary disease, or smoker’s lung. According to GSK, patients treated with Nucala and maintenance inhaled therapy for 104 weeks had a lower average annual rate of moderate to severe exacerbations than those taking a placebo.
BELIEBTE BEITRÄGE
Bluetongue outbreak in a Portuguese sheep farm has broken out
September 19, 2024
Austria says disaster fund to rise to 1 billion euros
September 19, 2024
Portugal gets help from Spain and Morocco in response to fires
September 19, 2024
Drought reduces Amazon rivers to historic lows
September 19, 2024
LIVEÜBERTRAGUNG